- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02061085
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment (MERIBEL)
A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes
Multicentre, prospective, non-controlled phase II clinical trial to evaluate the efficacy and tolerability of first line single agent Eribulin in patients with HER2-negative metastatic breast carcinoma previously exposed to taxanes for early stage.
The primary objective of the study is to determine the median time to progression achieved with Eribulin. Other secondary objectives will be; overall response rate, clinical benefit rate, time to treatment progression, duration of response and toxicity profile.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Madrid, Espanha
-
Valencia, Espanha
-
-
Aragón
-
Zaragoza, Aragón, Espanha
-
-
Asturias
-
Oviedo, Asturias, Espanha
-
-
Castilla Y León
-
Salamanca, Castilla Y León, Espanha
-
-
Cataluña
-
Barcelona, Cataluña, Espanha
-
-
Extremadura
-
Badajoz, Extremadura, Espanha
-
-
Galicia
-
La Coruña, Galicia, Espanha
-
-
Illes Balears
-
Palma de Mallorca, Illes Balears, Espanha
-
-
Islas Canarias
-
Gran Canaria, Islas Canarias, Espanha
-
-
Navarra
-
Pamplona, Navarra, Espanha
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histologically confirmed metastatic breast cancer HER2 negative, stage IIIb/IV
- Previous history of early disease (stage I-IIIb), surgically resected and treated with standard chemotherapy for at least 12 weeks at which included a taxane or ixabepilone
- Patients must have progressed in the 36 months after treatment with taxanes or ixabepilone.
- Age ≥ 18 years
- Given written informed consent
- Index of Eastern Cooperative Oncology Group (ECOG) of 0 or 1
- Patients must have recovered from toxicities related with previous treatment (CTC ≥ 1)
- Measurable or evaluable disease (RECIST 1.1)
- Adequate bone marrow function
- Adequate hepatic function
- Adequate renal function
- Life expectancy ≥ 3 months
Exclusion Criteria:
- Breast cancer patients initially diagnosed with local disease advanced or metastatic disease.
- Patients who have previously received cytotoxic therapy Hormone therapy permitted if the patients have interrupted it at least two weeks before the start of the study treatment.
- Major surgery or significant traumatic injury during the 4 weeks prior to study treatment or patients who may require major surgery during the assay.
- Brain metastases or leptomeningeal uncontrolled.
- Serious medical condition and / or not properly controlled (unstable angina, lung function severe impaired, uncontrolled diabetes, active serious infection,liver disease, HIV seropositivity, active bleeding diathesis)
- Other malignancies in the last three years, except: cervical carcinoma in situ, basal cell carcinoma or squamous cell skin carcinoma,that have been properly treated
- Patients who are pregnant or breastfeeding, or adults with reproductive capacity wich are not using effective contraception.
- Patients receiving chronic treatment with systemic corticosteroids or other immunosuppressive drugs (except corticosteroids with a daily dose equivalent to prednisone ≤ 20mg on a stable dose regimen one minimum of 4 weeks prior to study entry. Topical and inhaled corticosteroids are allowed
- Active alcoholism or drugs addiction documented.
- Prior history of noncompliance with medical regimens
- Patients who do not want or can not comply with the study protocol
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: monotherapy treatment with Eribulin
Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Median time to disease progression and treatment benefit variable
Prazo: Up to two years from the last dose
|
Up to two years from the last dose
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Objective response rate
Prazo: Up to one year from the first dose
|
Up to one year from the first dose
|
Clinical benefit rate
Prazo: Up to one year from the first dose
|
Up to one year from the first dose
|
Time until progression after the treatment
Prazo: Up to two years from the last dose
|
Up to two years from the last dose
|
Median duration of response
Prazo: Up to one year from the first dose
|
Up to one year from the first dose
|
Safety of eribulin in terms of adverse reactions
Prazo: Up to two years form the last dose
|
Up to two years form the last dose
|
Utility functional hepatic levels as criteria for dose modifications instead of the Child-Pugh classification system for the assessment of liver involvement
Prazo: Up to one year form the last dose
|
Up to one year form the last dose
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Antonio Llombart, MD, Valencia
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- OBU-SW-H-02
- 2012-004463-41 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Eribulina
-
Centre Georges Francois LeclercConcluído